The $100 million investment, will help it continue to “set the standard” for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children, Pfizer said in a statement.
The expansion, which brings the total investment in the Singapore Nutrition Plant to $372 million, makes it one of the largest nutritional plants worldwide and will create more than 100 jobs.
Production capacity will increase by 50 percent.
“The expansion of our Singapore Nutrition Plant is one example of Pfizer's commitment to securing a healthy and sustainable future for our children,” said Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer. “Our most valuable resources are our children and our environment, and Pfizer seeks to protect both by ensuring that our products for infants and children are manufactured to the most rigorous of safety and quality standards, with minimal environmental impact.”
Pfizer now hopes to increase supply to Singapore and key markets such as China, Indonesia, Malaysia, Pakistan, Sri Lanka, Thailand, Taiwan, Hong Kong and Vietnam.
“Infant Formula is one of the most stringently regulated consumer products in the world,” said Natale Ricciardi, Senior Vice President of Pfizer and President of Pfizer Global Manufacturing. “With about 120 colleagues working in Quality Operations alone, the plant maintains the highest quality and safety standards throughout every stage of the production process. Quality and compliance are critically important aspects of the Pfizer Global Manufacturing Culture.”
Lim Hng Kiang, Minister for Trade & Industry, Singapore, added: “Pfizer's expansion marks another significant milestone in the long-standing Pfizer-Singapore partnership.”
Edited by Chris Farnell